Qube Research & Technologies LTD Esperion Therapeutics, Inc. Transaction History
Qube Research & Technologies LTD
- $93.8 Billion
- Q2 2025
A detailed history of Qube Research & Technologies LTD transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Qube Research & Technologies LTD holds 485,603 shares of ESPR stock, worth $869,229. This represents 0.0% of its overall portfolio holdings.
Number of Shares
485,603
Previous 143,536
238.31%
Holding current value
$869,229
Previous $206,000
130.58%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding ESPR
# of Institutions
195Shares Held
121MCall Options Held
171KPut Options Held
679K-
Black Rock Inc. New York, NY14MShares$25 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.7MShares$21 Million0.0% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT10.3MShares$18.5 Million0.05% of portfolio
-
Two Seas Capital LP Rye, NY9.95MShares$17.8 Million0.18% of portfolio
-
Pender Fund Capital Management Ltd. Vancouver, A16.68MShares$12 Million4.26% of portfolio
About Esperion Therapeutics, Inc.
- Ticker ESPR
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 66,551,600
- Market Cap $119M
- Description
- Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...